Loading patent…
AssigneeRespivert Limited
InventorsKazuhiro Ito, Peter Strong, William Garth Rapeport, Peter John Murray, John King-Underwood, Jonathan Gareth Williams, Stuart ONIONS, Catherine Elisabeth Charron
Estimating the term…
The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.
1-9. (canceled)
A method of treatment or prevention of respiratory viral infections in patients comprising administering to a subject in need thereof an effective amount of the compound of the formula:
A method of treatment or prevention of respiratory viral infections in patients with chronic conditions selected from congestive heart failure, diabetes, cancer, or in immunosuppressed patients, said method comprising administering to a subject in need thereof an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, including all stereo isomers and tautomers thereof:
Dependencies are inferred from the claim text.